Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Company Overview

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $3.29 to $3.53
• 50-Day Range: $3.14 to $4.67
• 52-Week Range: $3.08 to $11.40
• Volume: 239,432 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $281.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.30
• Consensus Rating: Moderate Buy

Terns Pharmaceuticals Stock Analysis - MarketRank™

Terns Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 162nd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Terns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Terns Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Terns Pharmaceuticals is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Terns Pharmaceuticals is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Terns Pharmaceuticals has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.74% of the float of Terns Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Terns Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Terns Pharmaceuticals has recently increased by 4.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Terns Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Terns Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

9.74% of the float of Terns Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Terns Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Terns Pharmaceuticals has recently increased by 4.56%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.58

News Sentiment

Terns Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Terns Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for TERN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $211,040.00 in company stock.

Percentage Held by Insiders

15.10% of the stock of Terns Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TERN Stock Analysis - Frequently Asked Questions

How have TERN shares performed this year?

Terns Pharmaceuticals' stock was trading at $5.54 at the beginning of the year. Since then, TERN shares have decreased by 40.2% and is now trading at $3.3150.
View the best growth stocks for 2025 here.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released its quarterly earnings results on Thursday, March, 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06.

When did Terns Pharmaceuticals IPO?

Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

Who are Terns Pharmaceuticals' major shareholders?

Terns Pharmaceuticals' top institutional investors include Soleus Capital Management L.P. (9.59%), Schonfeld Strategic Advisors LLC (5.59%), Vanguard Group Inc. (4.56%) and Nuveen Asset Management LLC (3.10%). Insiders that own company stock include Orbimed Advisors Llc, Biosciences Fund V LP Lav, Vivo Opportunity, Llc, Mark J Vignola, Emil Kuriakose, Amy L Burroughs, Melita Sun Jung and Jill M Quigley.
View institutional ownership trends.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Terns Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TERN
• CIK: 1831363
• Web: www.ternspharma.com
• Phone: 650-525-5535
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.30
• High Stock Price Target: $26.00
• Low Stock Price Target: $7.50
• Potential Upside/Downside: +421.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-90,210,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.76%
• Return on Assets: -31.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 32.99
• Quick Ratio: 32.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.13 per share
• Price / Book: 0.85

Miscellaneous

• Outstanding Shares: 84,939,000
• Free Float: 72,113,000
• Market Cap: $298.14 million
• Optionable: Not Optionable
• Beta: -0.30